Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H31F3O |
Molecular Weight | 356.4654 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 4 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(F)(F)F
InChI
InChIKey=PLWROONZUDKYKG-DOFZRALJSA-N
InChI=1S/C21H31F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(25)21(22,23)24/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3/b7-6-,10-9-,13-12-,16-15-
Molecular Formula | C21H31F3O |
Molecular Weight | 356.4654 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 4 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25971887
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25971887
Arachidonyltrifluoromethane (more known as arachidonyl trifluoromethyl ketone) is a potent and selective slow binding inhibitor of the cytosolic phospholipase A2 (cPLA2). This compound is commonly used in the study of cPLA2-related neurodegenerative diseases. It was shown, that arachidonyl trifluoromethyl ketone decreased the levels of injurious lipid mediators, reduced pain, improved functional deficits, and conferred protection against lumbar spinal canal stenosis (LSS) injury. Thus, it shows potential for preclinical evaluation in LSS.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P47712 Gene ID: 5321.0 Gene Symbol: PLA2G4A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8195210 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain. | 2008 Dec |
|
Initial and extended inflammatory messages of the nongenomic signaling pathway of the TCDD-activated Ah receptor in U937 macrophages. | 2008 Dec 15 |
|
Significance of the nongenomic, inflammatory pathway in mediating the toxic action of TCDD to induce rapid and long-term cellular responses in 3T3-L1 adipocytes. | 2008 Dec 30 |
|
Characterization of the pattern of the nongenomic signaling pathway through which TCDD-induces early inflammatory responses in U937 human macrophages. | 2009 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25971887
in rats: arachidonyl trifluoromethyl ketone, ATK (7.5 mg/kg) was administered by oral gavage at 2 h following the cauda equina compression (CEC). ATK treatment of CEC animals reduced the phosphorylation of cPLA2 (pcPLA2) determined by Western blot, improved locomotor function evaluated by rotarod task, and reduced pain threshold evaluated by mechanical hyperalgesia method.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8195210
Arachidonyl trifluoromethyl ketone (AACOCF3) inhibited the release of AA from calcium ionophore-challenged U937 cells (IC50 = 8 microM, 2 x 10(6) cells ml-1) and from platelets (IC50 = 2 microM, 4 x 10(7) cells ml-1). AACH(OH)CF3 did not inhibit the production of AA in the ionophore-challenged cells. In addition to the release of AA, AACOCF3 also inhibited the production of 12-hydroxyeicosatetraenoic acid (12-HETE) and thromboxane B2, two of the major metabolites of AA produced by platelets
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:43:55 GMT 2025
by
admin
on
Mon Mar 31 19:43:55 GMT 2025
|
Record UNII |
00XIW1CR0F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
149301-79-1
Created by
admin on Mon Mar 31 19:43:55 GMT 2025 , Edited by admin on Mon Mar 31 19:43:55 GMT 2025
|
PRIMARY | |||
|
5280436
Created by
admin on Mon Mar 31 19:43:55 GMT 2025 , Edited by admin on Mon Mar 31 19:43:55 GMT 2025
|
PRIMARY | |||
|
2341
Created by
admin on Mon Mar 31 19:43:55 GMT 2025 , Edited by admin on Mon Mar 31 19:43:55 GMT 2025
|
PRIMARY | |||
|
C081565
Created by
admin on Mon Mar 31 19:43:55 GMT 2025 , Edited by admin on Mon Mar 31 19:43:55 GMT 2025
|
PRIMARY | |||
|
Arachidonyl trifluoromethyl ketone
Created by
admin on Mon Mar 31 19:43:55 GMT 2025 , Edited by admin on Mon Mar 31 19:43:55 GMT 2025
|
PRIMARY | |||
|
DTXSID901017144
Created by
admin on Mon Mar 31 19:43:55 GMT 2025 , Edited by admin on Mon Mar 31 19:43:55 GMT 2025
|
PRIMARY | |||
|
00XIW1CR0F
Created by
admin on Mon Mar 31 19:43:55 GMT 2025 , Edited by admin on Mon Mar 31 19:43:55 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |